




BMJ Open BabyBreathe trial: protocol for a randomised controlled trial of a complex intervention to prevent postpartum return to smoking

Caitlin Notley ¹, Tracey J Brown ¹, Linda Bauld ², Allan B Clark,³ Sharon Duneclift,⁴ Vicky Gilroy,⁵ Tess Harris ⁶, Wendy Hardeman,⁷ Richard Holland,⁸ Gregory Howard,³ Mei-See Man,³ Felix Naughton ⁷, Dan Smith,⁹ David Turner,³ Michael Ussher^{6,10}

To cite: Notley C, Brown TJ, Bauld L, *et al.* BabyBreathe trial: protocol for a randomised controlled trial of a complex intervention to prevent postpartum return to smoking. *BMJ Open* 2023;**13**:e076458. doi:10.1136/bmjopen-2023-076458

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-076458>).

Received 11 June 2023
Accepted 04 August 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Professor Caitlin Notley;
C.Notley@uea.ac.uk

ABSTRACT

Introduction Many people quit smoking during pregnancy, but postpartum smoking relapse is common. Maintaining smoking abstinence achieved during pregnancy is key to improving maternal and child health. There are no evidence-based interventions for preventing postpartum smoking relapse. This trial aims to determine whether an intervention to prevent postpartum relapse is effective and cost-effective.

Methods and analysis A randomised controlled trial of a complex intervention to prevent postpartum smoking relapse (BabyBreathe), with internal pilot, economic and process evaluations. Participants are adults who are pregnant and who report having quit smoking in the 12 months before, or during pregnancy. Participants are eligible if they read and understand English, and provide informed consent. Following consent and biochemical validation of smoking abstinence, participants are randomised to intervention or usual care/control (no specific relapse prevention support). The BabyBreathe intervention consists of manualised advice from a trained member of the health visiting service, health information leaflets for participants and partners, access to the BabyBreathe website and app. At the time of birth, participants are posted the BabyBreathe box and support is provided by text message for up to 12 months postpartum. Target sample size is 880, recruiting across midwifery services at four hubs in England and Scotland and through remote advertising in England, Scotland, Wales and Northern Ireland. Outcomes are collected at 6 and 12 months. The primary outcome is self-reported sustained smoking abstinence at 12 months, carbon monoxide verified. Secondary outcomes include self-reported abstinence, time to relapse, partner smoking status and quality of life.

Ethics and dissemination The trial was approved by the North West Preston Research Ethics committee (21/NW/0017). Dissemination will include publication in peer-reviewed journals, presentation at academic and public conferences including patient and public involvement and to policymakers and practitioners.

Trial registration number ISRCTN70307341

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This is the largest international trial of a postpartum smoking relapse prevention intervention, specifically developed to support sustained postpartum smoking abstinence.
- ⇒ The intervention (BabyBreathe) is theory based, drawing on behaviour change techniques, systematic reviews of existing evidence and extensive patient and public involvement.
- ⇒ An embedded mixed-methods process evaluation will assess implementation, mechanisms of impact and contextual influences, as well as acceptability and which elements of the intervention are perceived to be most effective, for which women, in which circumstances.
- ⇒ The study is resource intensive and is limited by the capacity of clinical services. The trial protocol allows flexible options for recruitment and intervention delivery to support clinical teams in delivering the intervention.
- ⇒ The trial is recruiting across the UK and includes a cost-effectiveness evaluation.

INTRODUCTION

Around a quarter of UK women report smoking in the year before pregnancy.^{1–3} More women quit smoking during pregnancy than at any other time, with as many as 45% able to ‘spontaneously quit’.⁴ However, there are marked health inequalities, as younger mothers and women with lower income are both less likely to quit and more likely to relapse.^{5,6} There is a unique opportunity to help women who cease smoking in pregnancy to quit permanently. Most women who quit smoking wish to remain abstinent after the birth; however, up to three-quarters of spontaneous quitters return to smoking within 6 months.⁷ Postpartum relapse is a major public health problem; yet there

are no evidence-based interventions, and no routine support is offered to prevent relapse.⁸ The National Health Service (NHS) Long Term Plan prioritises smoking cessation services in pregnancy,⁹ overlooking postpartum support. Supporting sustained abstinence may be critical to reaching the UK government 'smoke-free 2030' target.¹⁰ This trial will build on the success of cessation interventions in pregnancy,¹¹ by trialling a theory-based relapse prevention intervention developed by our team.¹²

Previous interventions to support sustained smoking abstinence post partum consist of brief and skills-based education, but when pooled, studies overall did not demonstrate effectiveness.¹³ A recent Cochrane review of relapse prevention interventions included postpartum relapse prevention trials as a subgroup. Fifteen studies included postpartum follow-up but there was no significant benefit of interventions.⁸ New approaches are urgently needed to address this global public health issue. The recent Cochrane review concludes that: 'Future studies may be better advised to focus on alternative approaches not studied extensively or at all so far, such as opportunistic use of nicotine replacement, contingency management, social support, cue exposure (only imaginary exposure has been studied so far), interventions aimed at maintaining abstainers' morale and awareness of the danger of slips, and so forth'.⁸ Sustained postpartum smoking abstinence has significant health benefits for the mother, as most new mothers will be young enough to minimise long-term harm, particularly from cancers and cardiovascular disease.¹⁴ Maternal smoking is the primary source of infant and child secondhand smoke exposure,^{15 16} a substantial cause of ill health and mortality.¹⁷ This has an intergenerational effect: children of smoking mothers are twice as likely to become smokers.¹⁸ The total NHS annual cost of smoking continuation, or returning to smoking following pregnancy, is estimated to range between £8.1 and £64 million annually for treating maternal health problems alone.¹⁹ While, in 2015/2016 the cost of admitted patient care in children attributable to passive smoking in England was an additional £5–12 million.²⁰

Following our comprehensive intervention development work and patient and public involvement, it is clear that postpartum smoking relapse is a complex problem requiring a multifaceted solution. Our research team have developed a novel intervention combining behavioural, digital and relapse prevention support, 'BabyBreathe'. The intervention is theory based and uses behaviour change techniques, each supported by available evidence.²¹ The development process involved working with pregnant and post-partum people, families and healthcare professionals to design an intervention that would fit in and work alongside usual care (universal health visiting service in the UK), be feasible to implement in practice and be acceptable.¹²

AIMS AND OBJECTIVES

Aim

To assess the effectiveness and cost-effectiveness of the BabyBreathe intervention in comparison to usual care, for supporting long-term smoking abstinence for mothers who have recently given birth and have stopped smoking during pregnancy or during the 12 months prior to pregnancy.

Objectives

1. To run an internal pilot study, with clear stop/go trial embedded criteria, primarily to test recruitment systems.
2. To definitively test the effectiveness of BabyBreathe in comparison with usual care, by comparing smoking abstinence rates at 12 months postpartum between trial groups.
3. To undertake a cost-effectiveness analysis of BabyBreathe in comparison with usual care based on healthcare resource use of mother and infant and maternal health-related quality of life (HRQoL).
4. To undertake an embedded mixed-methods process evaluation to assess delivery, implementation, fidelity and contamination and to identify mechanisms of action by exploring which intervention components may be particularly effective, for which women, in which contexts.

METHODS AND ANALYSIS

This protocol is reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials recommendations²² and the Template for Intervention Description and Replication (TiDIER) guidelines²³ (see online supplemental file).

Trial design

BabyBreathe is a multicentre, two-arm, superiority, parallel group, individually randomised, controlled trial of a complex intervention to prevent return to tobacco smoking postpartum, with internal pilot, including economic evaluation and process evaluation.

Study setting

The setting is 'real world' with the intervention integrated into, or offered as an adjunct to, standard antenatal and postnatal care. Trial recruitment hubs (Norfolk, London, North East of England, and Lothian, Scotland) have been selected to ensure a diverse sample, with an additional 'remote' recruitment hub to maximise recruitment rates (across the UK, including Wales and Northern Ireland).

Patient and public involvement

Two abstinent postpartum women were involved in development of intervention materials, and are included as members of our trial steering group, to advise on study progress and dissemination.

Population

We will seek pregnant people who have quit tobacco smoking in the 12 months before or during pregnancy,

where smoking abstinence is defined as having stopped smoking for at least 4 weeks prior to recruitment.

Inclusion criteria

1. Pregnant people who have stopped smoking completely in the 12 months prior to pregnancy, or at any time during pregnancy.
2. At 26 weeks gestation or any time following this up until birth, participant confirms having not smoked a single puff of a cigarette for at least 4 weeks.
3. Able to read and understand English.
4. Willing and able to give informed consent for participation in the study.
5. Expired carbon monoxide (CO) reading less than four parts per million (ppm).²⁴

Exclusion criteria

Under the age of 16.

Recruitment and screening

Multiple recruitment strategies will be used to reach target sample size (n=880). Potential participants will be identified by hospital and community midwives, research midwives (Clinical Research Network, CRN) or sonographers, during routine antenatal appointments (eg, booking appointment, routine scan appointment for dating or fetal anomaly scan) or by screening medical records. Participants may also be identified by smoke-free services, health visitors or by self-referring (eg, via adverts in health or community settings, using targeted online recruitment or media adverts). Potential participants will be screened for eligibility by the midwife (or by other healthcare professionals, in other health settings), or by a study researcher for direct referrals. The screening process can take place at any time during pregnancy, though the target is to identify participants ahead of 26 weeks pregnancy.

Eligible participants will be provided a brief patient information leaflet, either directly or indirectly via an online link, explaining the study and permission will be requested to pass their contact details to the research team. A health professional or a research team member will enter their details into a study database (Research Electronic Data Capture (REDCap)²⁵) that will automatically generate a short messaging service (SMS)/email to an electronic patient information sheet and e-consent form containing full reassurance of confidentiality. If participants are unable or unwilling to consent electronically, study researchers will contact potential participants by telephone to complete consent. Once consent is completed, participants will provide further details so they can be contacted from 26 weeks pregnancy with the link to the eligibility confirmation questionnaire.

Participants will be asked to confirm eligibility by replying via a link sent by text or email (according to preference), and will provide their address to enable postage of a CO monitor (iCO monitor, Bedfont) in order to confirm eligibility using an expired CO reading of less

than 4 ppm (this is the standard cut-off used in pregnancy).²⁴ Participants will be asked to download the study specific CO monitor application (iCOBabyBreathe) which will provide the REDCap database with two CO readings. The highest of the two readings will be recorded. Where CO readings ≥ 26 weeks gestation are able to take place in person as part of standard care, CO readings may be obtained by a member of the clinical team or a researcher to confirm participant eligibility.

Once the participant has given informed consent and eligibility is confirmed through a CO reading, a link will be automatically generated through text/email to the participant to complete the baseline questionnaire.

Randomisation

Completion and submission of the baseline measures will trigger randomisation (see trial flow diagram, figure 1). Participants will be individually randomised in a 1:1 ratio to the control or intervention groups using a computerised web-based randomisation system managed and accessed only by Norwich Clinical Trials Unit, to ensure adequate sequence generation and allocation sequence concealment. The randomisation system will stratify by recruitment hub, partner smoking status (partner smoking and partner non-smoking/no partner) and time of quit (before or during pregnancy), as these factors are likely to predict relapse.

Blinding

Blinding is not possible due to the nature of the trial and intervention. The primary outcome is objectively assessed using biochemically validated CO verified smoking abstinence. Therefore, we consider that there is low risk of bias for the primary outcome.

Internal pilot

The Independent Data Monitoring and Ethics Committee and Independent Trial Steering Committee (TSC) will scrutinise recruitment and protocol fidelity at 6 months into recruitment to establish continuation or stopping the trial at the pilot stage.

Trial allocation groups

Control

Control participants will receive usual antenatal and postnatal care as per the NHS maternity care pathway (ie, no routine relapse prevention support). Usual care varies across the UK and sites have been purposively selected to reflect the variations in routine care. Commonalities in usual care across all the sites include pregnant women being routinely screened for smoking status by their midwife at their first antenatal booking appointment. If a participant reports to be currently smoking, or has a CO reading of 4 ppm or more, they are automatically referred for stop smoking support via NHS commissioned stop smoking services (opt-out referral). Midwifery support focuses on abstinence in pregnancy and only includes brief advice about the opportunity to maintain abstinence postpartum and in the long-term. The usual




Figure 1 Trial flow diagram. CO, carbon monoxide; PIS, patient information sheet.

care group will receive standard ante and postnatal care, as per mandated midwifery and health visitor contacts. These visits may be face-to-face appointments, or they may be remote video or telephone appointments due to the COVID-19 pandemic and local service provision protocols.

Intervention

Intervention participants will receive usual care plus the BabyBreathe package of support. The BabyBreathe

intervention is informed by the Capability Opportunity Motivation-Behaviour model (COM-B) and Behaviour Change Wheel,²⁶ with full consideration of post partum context-specific concerns. The intervention is a package of support designed to be delivered at low cost alongside usual care and existing healthcare services. All intervention components have been developed and initially tested in our preliminary work with pregnant and postpartum

people and partners (MRC MR/PO16944/1).¹² The intervention comprises three main stages:

Antenatal support up to birth

- A. Usual care provision (as delivered in any given site area) will continue also to be provided to the intervention group.
- B. BabyBreathe relapse prevention leaflet.
- C. Partner/friend/relative relapse prevention leaflet—content has been designed to encourage partners/friends/relatives to support the participant to stay smoke free after delivery, and to promote active cessation for partners/friends/relatives themselves, where needed.
- D. Brief advice from a health visitor, health visiting team member or member of the research team trained to deliver the intervention (in-person, or remote). This advice is standardised and scripted following a protocol, with tailored options including positive praise for achieving smoking abstinence and brief advice about the importance of staying smoke-free. Active signposting to the BabyBreathe digital/remote elements are included in this discussion.
- E. Electronic CO testing—participants are given an iCO monitor (Bedfont) for individual use. Those in the intervention group will be encouraged to use the iCO monitor to self-monitor CO levels at any time during the study (control participants are only prompted to submit a research reading at baseline and study end).
- F. BabyBreathe website and app—these resources have been specifically developed and the app operates on both Android and iOS (iPhone) operating systems. The website and app can be accessed using a unique code. Users may input details such as the date they quit smoking, their estimated delivery date and may access self-help support, health information and advice, including innovative motivational tools, such as a health calendar and a closed online social support group, in preparation for entering the immediate postpartum period.
- G. At each subsequent health visitor contact (in-person, or remote), support for maintaining smoking abstinence will be briefly reiterated alongside usual care, where possible.

Immediate postnatal period

- H. BabyBreathe box—once the site team is alerted about the birth and input these data into the REDCap database, the central trial team will post out a BabyBreathe box. This is a physical box, designed to fit through a letter-box. The box includes self-incentive tools (eg, reward chart, journal, photograph frame), free preventative Nicotine Replacement Therapy (NRT, Nicorette Icy White 2mg, 30 pieces), plus advice and support to use NRT or e-cigarettes for relapse prevention.
- I. SMS or app notification tailored support—This will be triggered by the birth notification, delivering a programme of tailored relapse prevention messages.

Messages start daily, with a diminishing schedule over 12 months. At regular intervals participants are asked to confirm smoking status, and either then stay on the ‘smokefree’ or ‘lapse’ track of tailored messages. There is the option to opt out by texting ‘stop’ at any time.

Postnatal period and beyond

- J. At home/virtual postnatal visit with a health visitor, associated practitioner or BabyBreathe intervention trained researcher at around 10–14 days postpartum, when care is handed over from midwives to health visitors. At this visit, the health visitor will discuss smoking status, give positive praise, offer relapse prevention support, affirm that the BabyBreathe box has been received and discuss contents of the BabyBreathe box, and text/app message use.
- K. Reiteration of support from health visitors or associated practitioners, up to 12 months postpartum—all subsequent postpartum routine health visitor appointments for the duration of the study will be undertaken by the same health visitor or health visiting team member where possible, to assure continuity of care, which would be anticipated as part of usual practice. Positive praise will be offered for sustained smoking abstinence and the importance of relapse prevention will be emphasised. Participants will be encouraged to continue to engage, or to re-engage, with the full suite of BabyBreathe resources. Cessation support (referral) will be offered to partners where necessary and appropriate. For those who relapse, referral for cessation support will also be offered.

See [figure 2](#), for examples, of the components of the BabyBreathe intervention.

Outcomes

See [table 1](#) for participant timeline of interventions and assessments.

Primary outcome

The primary effectiveness outcome is self-reported continuous smoking abstinence, from birth, biochemically validated by CO monitoring at 12 months postpartum, with cut-off of less than 8 ppm (ie, a reading of 7 ppm or less) for those who are not pregnant, or with a cut-off of less than 4 ppm if they are pregnant at this time point, according to the Russell standard.²⁷ Adapting the Russell standard for the postpartum population, we will grant a period of ‘grace’, allowing up to five smoking lapses (a one off instance of smoking) between the birth of the baby and the 12-month follow-up, before the outcome is counted as relapse. Participants will provide CO readings electronically, using the iCO monitor (Bedfont) and study app (iCOBabyBreathe) provided at baseline. Participants will provide the REDCap database with two CO readings at entry and follow-up. The highest of the readings will be recorded. Where CO readings take place in person as part of standard care, or research visits, or

Figure 2: Examples of BabyBreathe Intervention Components




Figure 2 Examples of BabyBreathe intervention components.

when participants request help with taking a CO reading, these readings may be used.

Secondary outcomes

Secondary outcomes (table 1) measured at 6 and 12 months post partum by online self-report, or researcher follow-up, include self-reported point prevalence abstinence, self-reported time to relapse, participant-reported partner smoking status, self-efficacy (single item, self-report), Edinburgh Postnatal Depression Scale,²⁷ behavioural support use (eg, support from a stop smoking service), nicotine product use, perceived stress,²⁸ the Alcohol Use Disorders Test for Consumption (AUDIT-C),²⁹ health related quality of life (HRQoL) using the EQ-5D-5L.³⁰ Infant health outcomes (eg, minor infections requiring General Practitioner (GP) visits and more serious ill health requiring hospitalisation), participant and infant health resource use and cost-effectiveness will be measured at 12 months postpartum using a combination of GP patient records and participant self-report.

Sample size

If the primary outcome (continued smoking abstinence) occurs in 25% of the control group (based on an estimated relapse rate of 75%¹³) compared with 35% of the intervention group, then we estimate that we will need 880 participants (440 per group) to have 90% power to detect this 10% between group difference at the 5% level of significance. We estimate this difference between control and intervention groups is realistic based on recent trials.³¹ Loss to follow-up or withdrawal is not considered within the sample size calculation, as all those

lost to follow-up will be counted as returned to smoking, as is the usual convention in smoking cessation trials.³²

Retention

To maximise retention and minimise loss to follow-up, we will make the following efforts to retain contact with study participants. There will be one text/email reminder sent if links to questionnaires/forms are not followed by participants. If participants have not followed the initial links or reminders, then study researchers will contact up to five times to offer support and collect self-report data where possible. Outcome data collection at 6 and 12 months flexibly includes electronic, phone, post and face-to-face options. Participants will also be offered reimbursement for their time (£15 shopping voucher) on completion of 12-month follow-up.

Data analysis

We will use descriptive statistics to present the baseline characteristics of the two study groups. We will use χ^2 tests to compare follow-up rates between the study groups, to establish whether there is differential drop out. Analysis of smoking status will be based on the intention-to-treat principle by analysing individuals according to the treatment they were allocated to regardless of compliance. Individuals for whom we do not have the primary outcome data will be assumed to have returned to smoking. Analysis of the primary outcome will be based on a logistic regression model, adjusting for the stratification variables used in the randomisation algorithm. Secondary analysis will adjust for factors known to be predictive of relapse which will be agreed with the TSC and added to the statistical

Antenatal	Postnatal

[illegible]

*Potential participants will be variously identified during pregnancy: identified at pregnancy booking visit, at dating scans at (8–12 weeks) and/or 20-week scan, by screening records, or at routine care pregnancy appointments occurring anytime between start of pregnancy and 26 weeks of pregnancy, and by self-referral through responding to adverts. These practices will vary and due to pandemic-related restrictions of appointments that may happen remotely. Those missed can be eligible for recruitment following 26 weeks of pregnancy, until the end of pregnancy.

analysis plan (SAP) prior to analysis. Secondary outcomes will be analysed in a similar fashion using a general linear model. Missing data patterns will be examined, and if appropriate, multiple imputation will be undertaken. The SAP is preregistered (on the Open Science Framework (OSF))—see online supplemental appendix 1. The analysis plan may include analysis suggested by the qualitative analysis, such as subgroup analysis or mediation analysis. Any analysis will be prespecified before data lock and published in the SAP prior to any data analysis.

Economic evaluation

An economic analysis will be conducted as an integral part of the randomised controlled trial. The primary perspective will be the NHS and social care; however, we will also look at broader relevant costs such as purchase of nicotine replacement therapies. All resources required to provide BabyBreathe will be recorded: these will include staff time; equipment; consumables; required staff training; and any other relevant costs. For staff time to carry out specific tasks to provide BabyBreathe a variety of methods to obtain these data will be explored: these would include trial records on relevant expenditure and expert opinion. Healthcare resource use will be obtained from two sources. First, we will include a modified Client Service Receipt Inventory (CSRI) to obtain data by participant self-report at the 12-month follow-up. This will cover the following: maternal antenatal hospital admissions; details of delivery, including mode of delivery and length of stay; and infant neonatal intensive care unit admissions. Contacts with GP and practice nurses, contact with other primary care practitioners and referral to secondary care will also be collected as well as smoking cessation-related expenditure. Additionally, where feasible we will obtain data from patient notes and GP records. All resources identified during the study will be valued using appropriate local and national unit cost data.

The main outcome measure used in the economic analysis will be the study's primary outcome measure, continuous postpartum smoking abstinence. This will form a cost-effectiveness study looking at cost per additional sustained abstainer. Additionally, we will use EQ-5D-5L³⁰ values obtained from participants to undertake a cost utility analysis (ie, cost per QALY) estimating quality-adjusted life years (QALYs), obtained at baseline, 6 and 12 months postpartum. EQ-5D-5L questionnaires will be valued using the most appropriate scoring algorithm at time of analysis. Currently, this would be the UK mapped scores.³³ Cost and effectiveness data will be estimated using regression-based methods to allow for differences in baseline characteristics between groups. Non-parametric bootstrapping will be used to allow for uncertainty and this will also be used to construct a cost-effectiveness acceptability curve, which shows how likely the intervention is to be cost-effective at different monetary values of the effectiveness measures. A health economics analysis plan will be agreed and published on the OSF before any analysis of health economics data.

Process evaluation

Both qualitative and quantitative data will be collected by the study research team to assess implementation of the intervention, mechanisms of impact and contextual influences, as per Medical Research Council guidance^{34 35} (table 2).

Fidelity of intervention delivery (*implementation*) and participant engagement with the health visitor visits and website/app will be assessed quantitatively through logs of visits, data analytics for website/app usage (the number of times that systems are logged on to, which resources are accessed, the time of engagement, the delivery of support messages via notifications and text messages, the time of any disengagement, discontinuation of SMS or app notifications and self-reported engagement (as per³⁶). Qualitative analysis will be undertaken of social support group threads, for which consent will have been sought on recruitment to the study; and audio-recordings (health visitors, practitioners or BabyBreathe researchers will be asked to record approximately 10% of visits (≤10 min intervention only), antenatal as well as postnatal) and interviews with health visitors (n=12) and a qualitative interview subsample of participants and partners (n=40). Potential contamination between trial arms and protocol modifications will be assessed through qualitative interviews with health visitors and regular reporting by trial research teams. We will assess whether any identifiable modifications were planned adaptations to fit context, or unforeseen, and report our findings according to FRAME, an established framework.³⁷ To illuminate possible mechanisms of action, a combined analysis of qualitative participant interview data, audio-recordings (eg, intervention duration, delivery of behaviour change techniques) and quantitative engagement data across recruitment hubs will assess which components of the intervention were perceived to be particularly effective, for which people, in which contexts.

Data management

In view of the nature of the population (who are all expected to have one or more pregnancy-related hospitalisation and primary care attendances which will be recorded in medical records); the intervention (which is not a medicinal product with the exception of nicotine replacement therapy (gum) included in the BabyBreathe box; and the trial primary and secondary outcomes, we do not intend to collect any additional safety endpoints.

BabyBreathe trial team members review the trial database to generate reports and review data entry. The essential trial issues, events and outputs, including defined key data points, are discussed by the trial team on a weekly basis and with relevant committees when necessary. A data sharing statement is included in the trial registry entry.

Ethics and dissemination

Full research ethics committee (REC) and Health Research Authority (HRA) approval has been granted (REC reference: 21/NW/0017, IRAS Project ID: 291746,

Table 2 Components of the BabyBreathe mixed-methods process evaluation

Aims	Process evaluation component (Moore <i>et al</i> , BMJ 2015)	Method of data collection
Assess fidelity of BabyBreathe training	Implementation. Training.	Questionnaires before and after training
Assess fidelity of intervention contacts	Implementation (intervention contacts). Dose, reach, engagement.	Log of visits by health visitor, health visiting practitioner or researcher (participant level). Audio-recordings of 10% of contacts (antenatal and postnatal). Qualitative interviews (health visitors, members of the health visiting team or researcher—fidelity of delivery). Qualitative interviews (participants and partners—engagement with visits and type of staff delivering the intervention).
Assess fidelity/engagement with the website and application	Implementation (website/application). Dose, reach, engagement.	Website and application data (number of logins, total time in use). Social support group threads. Number of texts received. Discontinuation of text/application notifications. Qualitative interviews (participants).
Assess contamination between trial arms	Implementation (intervention contacts). Contamination.	Recorded by trial research teams at each recruitment hub. Qualitative interviews (health visitors, members of the health visiting team or researchers). Health visitor feedback groups.
Assess protocol modifications	Implementation (intervention contacts, website/application). Fidelity, adaptations (intended and unintended/unforeseen; positive adaptations or drift).	Recorded by trial research teams at each recruitment hub. Qualitative interviews (health visitors, members of the health visiting team or researchers). Health visitor, member of the health visiting team and researcher feedback groups.
Assess how the intervention worked	Mechanisms of impact: hypothesised and unintended/unexpected pathways.	Engagement data across recruitment hubs (visits). Engagement with website and application. Engagement with text support. Use of BabyBreathe box components (self-report, qualitative interviews and health visitor interviews). Qualitative interviews (participants).
Assess contextual influences on implementation and mechanisms of impact	Context: contextual influences, eg, participant/health visitor characteristics and geographical region, on implementation and mechanisms of impact.	Qualitative interviews with health visitors, members of the health visiting team, or researchers and participants.
Assess the impact of the COVID-19 pandemic on intervention delivery and participant efforts to remain quit/stop smoking (partner)	Implementation processes (health visitor perspective). Fidelity. Adaptions (by health visitors, members of the health visiting team or researchers). Context. COVID-19 pandemic response, eg, restrictions, (partial) lockdowns. Mechanisms of impact. Mediators.	Qualitative interviews with health visitors, members of the health visiting team, or researchers and participants.

protocol V.7 dated 04 May 2022). Participants provide electronic consent to take part, and rights of refusal to participate, or requests of withdrawal will be respected.

The results of the trial will be disseminated in open access journals, regardless of the direction of effect. The full protocol, statistical analysis plan, qualitative and health economics analysis plans and anonymised data sets will be published in an online open access repository.

Current study status

Recruitment opened in April 2021 and the first participant was randomised in September 2021. Recruitment is expected to take 24 months, with results expected to be published following final follow-up in late 2024 or early 2025.

Author affiliations

¹Norwich Medical School, University of East Anglia, Norwich, UK

²The Usher Institute, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK

³Norwich Clinical Trials Unit, Norwich Medical School, University of East Anglia, Norwich, UK

⁴Norfolk Healthy Child Programme, Norwich, UK

⁵Institute of Health Visiting, London, UK

⁶Population Health Research Institute, St Georges, University of London, London, UK

⁷School of Health Sciences, University of East Anglia, Norwich, UK

⁸Exeter Medical School, University of Exeter, Exeter, UK

⁹School of Computing Sciences, University of East Anglia, Norwich, UK

¹⁰Institute for Social Marketing and Health, University of Stirling, Stirling, UK

Twitter Caitlin Notley @AddictionUEA, Linda Bauld @LindaBauld, Sharon Dunecliff @sdunecliff and Felix Naughton @FelixNaughton

Acknowledgements We appreciate the support of the study sponsor, Norfolk & Waveney CCG. The study is led by researchers at the University of East Anglia (UEA) and managed by the Norwich Clinical Trials Unit (NCTU) at UEA. Our thanks go to all organisations involved in recruitment and in supporting delivery of the intervention, particularly health visiting services and midwifery services. We would also like to thank patient and public involvement (PPI) contributors. We acknowledge the contribution of the researchers at sites who underwent training to deliver the intervention. Oversight provided by the independent Trial Steering Committee, comprising: Lion Shahab (Chair), Jo Leonardi-Bee, Jinshou Li, Siobhan Paul (PPI rep), Michael Twigg (Host rep) and Hilary Wareing. Sue Cooper, Graham Horne (sponsor rep), John Waldron, Libby White (PPI rep) and Julie Wright (funder rep); and Independent Data Monitoring committee: Paul Aveyard (Chair), Emma Beard and Karen Whittaker (terms of reference available upon request).

Contributors CN and TJB conceived the study idea, and drafted the manuscript. CN, TJB, WH, DS, MU and FN developed the intervention. GH is the trial manager and M-SM is the senior trial manager. ABC is the trial statistician, DT is the health economist. LB, SD, VG, MU and TH are site principal investigators. RH provides public health academic trials expertise and DS provides computer science oversight.

Funding This study is supported by the National Institute for Health and Care Research (NIHR) Public Health Research programme (project reference NIHR129074). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Consent obtained directly from patient(s).

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Data availability statement Data will be made available on publication of the trial main results, as per our data sharing statement.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Caitlin Notley <http://orcid.org/0000-0003-0876-3304>

Tracey J Brown <http://orcid.org/0000-0003-4381-5974>

Linda Bauld <http://orcid.org/0000-0001-7411-4260>

Tess Harris <http://orcid.org/0000-0002-8671-1553>

Felix Naughton <http://orcid.org/0000-0001-9790-2796>

REFERENCES

- 1 Patnode CD, Henderson JT, Coppola EL, *et al*. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US preventive services task force. *JAMA* 2021;325:280–98.
- 2 Claire R, Chamberlain C, Davey M-A, *et al*. Pharmacological interventions for promoting smoking cessation during pregnancy. *Cochrane Database Syst Rev* 2020;3:CD010078.
- 3 Adult smoking habits in great Britain - office for National Statistics. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain> [Accessed 7 Aug 2019].
- 4 Lumley J, Chamberlain C, Dowswell T, *et al*. Interventions for promoting smoking cessation during pregnancy. *Cochrane Database Syst Rev* 2009;CD001055.
- 5 Letourneau AR, Sonja B, Mazure CM, *et al*. Timing and predictors of postpartum return to smoking in a group of inner-city women: an exploratory pilot study. *Birth* 2007;34:245–52.
- 6 Flemming K, Graham H, Heirs M, *et al*. Smoking in pregnancy: a systematic review of qualitative research of women who commence pregnancy as Smokers. *J Adv Nurs* 2013;69:1023–36.
- 7 Jones M, Lewis S, Parrott S, *et al*. Re-starting smoking in the postpartum period after receiving a smoking cessation intervention: a systematic review. *Addiction* 2016;111:981–90.
- 8 Livingstone-Banks J, Norris E, Hartmann-Boyce J, *et al*. Relapse prevention interventions for smoking cessation. *Cochrane Database Syst Rev* 2019;2:CD003999.
- 9 NHS England. Available: <https://www.england.nhs.uk/long-term-plan/> [Accessed 6 Mar 2019].
- 10 Smokefree. Smokefree action coalition. 2030. Available: <https://smokefreeaction.org.uk/smokefree2030/> [Accessed 19 Jan 2022].
- 11 Chamberlain C, O'Mara-Eves A, Porter J, *et al*. Psychosocial interventions for supporting women to stop smoking in pregnancy [Internet]. *Cochrane Database Syst Rev* 2017;2:CD001055.
- 12 Notley C, Brown TJ, Bauld L, *et al*. Development of a complex intervention for the maintenance of postpartum smoking abstinence: process for defining evidence-based intervention. *Int J Environ Res Public Health* 2019;16:1968.
- 13 Hajek P, Stead LF, West R, *et al*. Relapse prevention interventions for smoking cessation. *Cochrane Database Syst Rev* 2013;CD003999.
- 14 Doll R, Peto R, Boreham J, *et al*. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
- 15 Sims M, Tomkins S, Judge K, *et al*. Trends in and predictors of second-hand smoke exposure indexed by Cotinine in children in England from 1996 to 2006. *Addiction* 2010;105:543–53.
- 16 DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. *Pediatrics* 2004;113(Supplement_3):1007–15.
- 17 RCP. Passive smoking and children. 2018. Available: <https://shop.rcplondon.ac.uk/products/passive-smoking-and-children>
- 18 Leonardi-Bee J, Jere ML, Britton J. Exposure to parental and Sibling smoking and the risk of smoking uptake in childhood and

- adolescence: a systematic review and meta-analysis. *Thorax* 2011;66:847–55.
- 19 Godfrey C, Pickett KE, Parrot S, *et al.* *Estimating the costs to the NHS of smoking in pregnancy for pregnant women and infants.* Department of Health Sciences, The University of York, 2010.
- 20 Royal College of Physicians. *Hiding in plain sight. treating tobacco dependency in the NHS. A report by the tobacco advisory group of the Royal college of physicians;* 2018.
- 21 Brown TJ, Hardeman W, Bauld L, *et al.* A systematic review of behaviour change techniques within interventions to prevent return to smoking postpartum. *Addict Behav* 2019;92:236–43.
- 22 Chan A-W, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.
- 23 Hoffmann TC, Glasziou PP, Boutron I, *et al.* Better reporting of interventions: template for intervention description and replication (Tidier) checklist and guide. *BMJ* 2014;348.
- 24 Bailey BA. Using expired air carbon Monoxide to determine smoking status during pregnancy: preliminary identification of an appropriately sensitive and specific cut-point. *Addict Behav* 2013;38:2547–50.
- 25 Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (Redcap)—A Metadata-driven methodology and Workflow process for providing Translational research Informatics support. *J Biomed Inform* 2009;42:377–81.
- 26 Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for Characterising and designing behaviour change interventions. *Implement Sci* 2011;6:42.
- 27 Bunevicius A, Kusminskas L, Pop VJ, *et al.* Screening for Antenatal depression with the Edinburgh depression scale. *J Psychosom Obstet Gynaecol* 2009;30:238–43.
- 28 Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav* 1983;24:385–96.
- 29 Bush K, Kivlahan DR, McDonell MB, *et al.* The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). *Arch Intern Med* 1998;158:1789–95.
- 30 EQ-5D-5L – EQ-5D. Available: <https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/> [Accessed 8 Nov 2020].
- 31 Pollak KI, Fish LJ, Lyna P, *et al.* Efficacy of a nurse-delivered intervention to prevent and delay postpartum return to smoking: the quit for two trial. *Nicotine Tob Res* 2016;18:1960–6.
- 32 West R, Hajek P, Stead L, *et al.* Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction* 2005;100:299–303.
- 33 van Hout B, Janssen MF, Feng Y-S, *et al.* Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value SETS. *Value Health* 2012;15:708–15.
- 34 Oakley A, Strange V, Bonell C, *et al.* Process evaluation in randomised controlled trials of complex interventions. *BMJ* 2006;332:413–6.
- 35 Craig P, Dieppe P, Macintyre S, *et al.* Developing and evaluating complex interventions: the new medical research council guidance [BMJ [Internet]]. *BMJ* 2008;a1655.
- 36 Groner J, French G, Ahijevych K, *et al.* Process evaluation of a nurse-delivered smoking relapse prevention program for new mothers. *J Community Health Nurs* 2005;22:157–67.
- 37 Wiltsey Stirman S, Baumann AA, Miller CJ. The FRAME: an expanded framework for reporting adaptations and modifications to evidence-based interventions. *Implement Sci* 2019;14:58.



The TIDieR (Template for Intervention Description and Replication) Checklist*:

Information to include when describing an intervention and the location of the information

Item number	Item	Where located **	
		Primary paper (page or appendix number)	Other [†] (details)
1.	BRIEF NAME Provide the name or a phrase that describes the intervention.	__Title page__	'Babybreathe'
	WHY		
2.	Describe any rationale, theory, or goal of the elements essential to the intervention.	__page 3__	_____
	WHAT		
3.	Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).	Page 6, 7	_____
4.	Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.	Page 6,7	_____
	WHO PROVIDED		
5.	For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.	__page 6, 7__	_____
	HOW		
6.	Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.	__page 6, 7__	_____
	WHERE		
7.	Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.	__page 6, 7__	_____

TIDieR checklist

WHEN and HOW MUCH		
8.	Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.	__page 7__
TAILORING		
9.	If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.	__page 6, 7__
MODIFICATIONS		
10.*	If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).	__N/A__
HOW WELL		
11.	Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.	__ page 10,11
12.*	Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.	__N/A__

** **Authors** - use N/A if an item is not applicable for the intervention being described. **Reviewers** – use ‘?’ if information about the element is not reported/not sufficiently reported.

† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL).

‡ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete.

* We strongly recommend using this checklist in conjunction with the TIDieR guide (see *BMJ* 2014;348:g1687) which contains an explanation and elaboration for each item.

* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a **randomised trial** is being reported, the TIDieR checklist should be used in conjunction with the CONSORT statement (see www.consort-statement.org) as an extension of **Item 5 of the CONSORT 2010 Statement**. When a **clinical trial protocol** is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of **Item 11 of the SPIRIT 2013 Statement** (see www.spirit-statement.org). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see www.equator-network.org).

TIDieR checklist






Babybreathe

A RANDOMISED CONTROLLED TRIAL OF A COMPLEX INTERVENTION TO PREVENT RETURN TO SMOKING IN WOMEN POSTPARTUM

Statistical Analysis Plan (SAP)

Version 1.0

04.06.2023

Name	Title	Signature	Date
Caitlin Notley	Chief Investigator		04.06.2023
Allan Clark	Statistician		07.6.2023
Lucy Clark	Trial Manager		07.06.2023

SAP REVISION HISTORY

Document Name	Version No.	Reason for Revision	Effective Date



1.0 Administrative Information

Sponsor : Norfolk and Norwich University Hospitals NHS Foundation Trust (NNUH)

Sponsor Reference : R207276

Funder : National Institute for Health Research – Health Technology Assessment

Funder Reference : NIHR129074

Trial Registration : ISRCTN70307341

IRAS: 291746

Chief Investigator : Caitlin Notley

Trial Statistician : Allan Clark

UKCRC Trials Unit : NCTU

Latest Protocol : Version 7.0



2.0 Introduction

2.1 Background and Rationale

This is provided in section 4.1 of the protocol.

2.2 Objectives

The overall trial objectives are provided in section 4.2 of the protocol, however this SAP covers the following

1. To run an internal pilot study, with clear stop/go trial embedded criteria, primarily to test recruitment systems.
2. To definitively test the real-world effectiveness of BabyBreathe in comparison with usual care, by comparing smoking abstinence rates at 12 months postpartum between trial groups.

3.0 Study Methods

3.1 Trial Design

A two-group, multi-centre, pragmatic, individually randomised, controlled trial with an internal pilot, and including economic evaluation and process evaluation.

Intervention: Intervention participants will receive usual care plus the BabyBreathe package of support. The BabyBreathe intervention is informed by the Capability Opportunity Motivation-Behaviour (COM-B) model and Behaviour Change Wheel (21), with full consideration of postpartum women's context-specific concerns. The intervention is a package of support designed to be delivered at low cost alongside usual care and existing healthcare services. All intervention components have been developed and initially tested in our preliminary work with women and partners (MRC MR/PO16944/1) (9). The intervention comprises three main stages:

1. Antenatal support up to birth:

- A.) BabyBreathe™ relapse prevention leaflet.
- B.) Partner/Friend/Relative relapse prevention leaflet – content has been designed to encourage partners/friends/relatives to support women to stay smoke free after delivery, and to promote active cessation for partners/friends/relatives themselves, where needed.
- C.) Brief advice from a health visitor, health visiting team member practitioner or member of the research team trained to deliver the intervention (in-person, or remote). This advice is standardised and scripted following a protocol, with tailored options including positive praise for achieving smoking abstinence, and brief advice about the importance of staying smoke-free. Active signposting to the BabyBreathe digital /remote elements are included in this discussion.
- D.) Electronic carbon monoxide testing – women are given an iCO monitor (Bedfont) for individual use. Intervention women will be prompted to use the iCO monitor to self-monitor CO levels at any time during the study (control participants will be restricted to use at baseline and study end).



- E.) BabyBreathe website and app – these resources have been specifically developed and operate on both android and iOS (iPhone) systems. The website and app can be accessed using a unique code by women for free. Women may input details such as the date they quit smoking, their estimated delivery date (EDD), and may access self-help support, health information and advice, including innovative motivational tools, such as a health calendar, and a closed online social support group, in preparation for entering the immediate postpartum period.
- F.) At each subsequent health visitor contact (in-person, or remote), support for maintaining smoking abstinence will be briefly reiterated alongside usual care, where possible.
- G.) Usual care provision (as delivered in any given site area) will continue also to be provided to the intervention group.

2. Immediate postnatal period

- H.) BabyBreathe box – once the site team are alerted about the birth and input these data into the REDCap database, the central trial team will post out a BabyBreathe box. This is a physical box, designed to fit through a letter-box. The box includes self-incentives (e.g. reward chart, journal, photograph frame), free preventative NRT (Nicorette Icy White 2mg), plus advice and support to use NRT or e-cigarettes for relapse prevention.
- I.) SMS or app notification tailored support – This will be triggered by the birth notification, delivering a programme of tailored relapse prevention messages that draw on data initially inputted by the user.

3. Postnatal period and beyond

- J.) At home/virtual postnatal visit with a health visitor, associated practitioner or BabyBreathe intervention trained researcher at around 10-14 days postpartum, when full? care of women and babies is handed over from midwives to health visitors. At this visit, the health visitor will discuss smoking status, give positive praise, offer relapse prevention support, affirm that the BabyBreathe box has been received, and discuss contents of the BabyBreathe box, and text/app message use.
- K.) Reiteration of support from health visitors or associated practitioners, up to 12 months postpartum – all subsequent postpartum routine health visitor appointments for the duration of the study will be undertaken by the same health visitor, health visiting team member, to assure continuity of care, which would be anticipated as part of usual practice. Positive praise will be offered for sustained smoking abstinence and the importance of relapse prevention will be emphasised. Women will be encouraged to continue to engage, or to re-engage, with the full suite of BabyBreathe resources. Cessation support (referral) will be offered to partners where necessary and appropriate. For women who relapse, referral for cessation support will also be offered.

Control:

Control participants will receive usual antenatal and postnatal care as per the NHS maternity care pathway (i.e. no routine relapse prevention support). Usual care varies across the UK and sites have been purposively selected to reflect the variations in routine care. Commonalities in usual care across all the sites include pregnant women being routinely screened for smoking status by their midwife at their



first antenatal booking appointment. If a woman reports that she is currently smoking, or she has a CO reading greater than 3ppm (i.e. a reading of 4ppm or more), she is automatically referred for stop smoking support via NHS commissioned stop smoking services (opt-out referral). Midwifery support focuses on abstinence in pregnancy and only includes brief advice about the opportunity to maintain abstinence postpartum and in the long-term. The usual care group will receive standard ante and postnatal care, as per mandated midwifery and health visitor contacts. These visits may be face-to-face appointments, or they may be remote video or telephone appointments due to the COVID-19 pandemic.

3.2 Allocation

Completion and submission of the baseline measures will trigger randomisation (see trial flow diagram, figure 1). Participants will be individually randomised 1:1 via a computerised randomisation system managed by Norwich Clinical Trials Unit, to ensure adequate sequence generation and allocation sequence concealment. The randomisation system will stratify by recruitment hub, partner smoking status (partner smoking and partner non-smoking/no partner) and time of quit (before or during pregnancy), as factors that are likely to predict relapse.

3.3 Sample Size

This is provided in section 5.8 of the protocol but is repeated below.

If the primary outcome (continued smoking abstinence) occurs in 25% of the control group (based on an estimated relapse rate of 75% (10)) compared with 35% of the intervention group, then we estimate that we will need 880 participants (440 per group, 220 per recruitment hub) to have 90% power to detect this 10% between group difference at the 5% level of significance. We estimate this difference between control and intervention groups is realistic based on recent trials (27). Loss to follow up or withdrawal is not considered within the sample size calculation, as all those lost to follow up will be counted as returned to smoking, as is the usual convention in smoking cessation trials (ref). From national data, we estimate that approximately 22% of women will be smoking in the 12 months prior to pregnancy.

3.4 Framework

This is a superiority framework comparing the intervention to the control.



3.5 Timing of outcome assessments

Table 1: BABYBREATHE PARTICIPANT TIMELINE

Schedule of enrolment, interventions, and assessments.

	Antenatal					Postnatal				
	Screening (From 8 weeks to birth)*	Confirm Eligibility (From 26 weeks)	Baseline (From confirmation of eligibility)	Health Visit (From randomisation up to birth)		Postnatal within 7 days	Health Visit (10-14 days Postpartum)	Health Visits (All subsequent routine)	6 month follow up	12 month follow up
Eligibility	X				Birth					
Consent to be contacted	X									
Link to PIS and Consent	X									
iCO reading to confirm eligibility		X								X
Demographics			X							
Smoking Status (SR)			X						X	X
Breastfeeding intention (ref)			X						X	X
Relapse Predictors			X						X	X
Self-Efficacy (SR)			X						X	X
Edinburgh Depression Scale (22)			X						X	X
Behavioural Support (SR)			X						X	X
Nicotine Product Use (SR)			X						X	X
AUDIT-C (23)			X						X	X
EQ-5D-5L (45)			X						X	X
Cohen 4 item Perceived stress scale (24)			X						X	X
Randomisation			X							
BabyBreathe Intervention				X		X	X	X	X	X
Birth Notification						X				
Healthcare Resource Use										X
Infant Health Outcomes										X



*Potential participants will be variously identified during pregnancy: identified at pregnancy booking visit, at dating scans at (8-12 weeks) and/or 20 week scan, by screening records, or at routine care pregnancy appointments occurring anytime between start of pregnancy and 26 weeks of pregnancy, and by self-referral through responding to adverts. These practices will vary and due to pandemic related restrictions of appointments that may happen remotely. Those missed can be eligible for recruitment following 26 weeks of pregnancy, until the end of pregnancy

3.6 Interim analyses and stopping guidance

There will be no formal interim analyses or stopping guidance. However, the trial does have progression criteria the end of the internal pilot stage after three months recruitment. These are listed below.

3.7 Timing of analyses

The internal pilot does not require the analysis of any outcomes or unblinded data so is not considered as 'analysis' for this SAP. The analysis will be done once the database is locked and the SAP approved once all of the outcome data has been collected.

4.0 Statistical Principles

4.1 Levels of statistical significance

A 5% level of significance and 95% confidence intervals will be used throughout.

4.2 Analysis populations

The ITT population is defined as the set of all randomized participants regardless of compliance. If participants are subsequently withdrawn from the study then their data will still be included and the missing data strategy detailed in the analysis section will be used. Individuals who are deemed to be post-randomisation exclusions will be excluded from the analysis.

A modified ITT population will exclude participants who had complications at birth. Analysis of this population will be made on the primary outcome only.

4.3 Treatment Adherence / received

Compliance of the intervention along with the treatment received will be reported as per the table below.



Table 4.3.1: Compliance / treatment received

	Intervention delivery
Antenatal support period	n (%)
Relapse prevention leaflet.	
Partner/Friend/Relative relapse prevention leaflet	
Brief advice from a health visitor	
Electronic carbon monoxide testing given	
BabyBreathe website and app provided / accessed	
Immediate postnatal period	
BabyBreathe box sent	
SMS or app notification sent	
SMS or app opt out received	
Postnatal period and beyond	
At home/virtual postnatal visit with a health visitor	
Reiteration of support from health visitors	
Number of postpartum visits	
None	
One	
Two	
Three	
Four	
...	

4.4 Protocol deviations

Protocol deviations will be discussed at the TMG and will be reported as a list.

5.0 Trial Population

5.1 Screening data

The following data and tables will be reported from the screening data.

Table 5.1.1: Screening data by month of approaching patient

Month of screening	Number of patients approached	Number interested in participating	Number eligible* (pre-screening)	Number giving consent	Number eligible **	Number randomised



Table 5.1.2: Reasons for declining

	Number (% Of those declining participation)	Percentage of those approached

5.2 Eligibility

5.2.1 Participant Inclusion Criteria

1. Those who are pregnant who have stopped smoking completely in the 12 months prior to pregnancy, or at any time during pregnancy.
2. At 26 weeks gestation or any time following this up until birth, woman confirms having not smoked a single puff of a cigarette for at least four weeks.
3. Able to read and understand English.
4. Willing and able to give informed consent for participation in the study.
5. Expired carbon monoxide (CO) reading less than four parts per million (ppm)

5.2.2 Participant Exclusion Criteria

6. Under the age of 16

This will be reported as below.

Table 5.2.1: Reasons for ineligibility

	Frequency (%) (N=)
Pre-screening eligibility criteria met	
Reason for exclusion (n=)	
Absences of inclusion criteria	
Those who are pregnant who have stopped smoking completely in the 12 months prior to pregnancy, or at any time during pregnancy.	
At 26 weeks gestation or any time following this up until birth, participant confirms having not smoked a single puff of a cigarette for at least four weeks.	
Able to read and understand English.	



Willing and able to give informed consent for participation in the study	
Expired carbon monoxide (CO) reading less than four parts per million (ppm)	
Presence of exclusion criteria	
Aged under 16	

5.3 Recruitment and participant flow

Table 5.3.1: Participant accrual (e.g. per time period, cumulative, if appropriate against predicted accrual in graphical form) for main participants (ITT population only)

Month of recruitment	Predicted	Actual	Cumulative Predicted	Cumulative Actual

Graph of predicted vs actual recruitment

A CONSORT diagram will also be produced.

5.4 Withdrawal information

Follow-up rates and reasons for withdrawal will be reported in the following tables.

Table 5.4.1: Follow-up

	ITT population	
	Control (n=)	Intervention (n=)
Lost to FU before birth		
Lost to FU month 0-6 post partum, n(%)		
Lost to FU month 7-12 post partum, n(%)		



Table 5.4.2: Reasons for loss to follow-up.

	ITT population		ITT+ population	
	Control (n=)	Intervention (n=)	Control (n=)	Intervention (n=)
Reason lost to follow (month 0-6)				
Reason 1, n(%)				
Reason 2, n(%)				
....				
Reason lost to follow (month 6-12)				
Reason 1, n(%)				
Reason 2, n(%)				
....				

5.5 Baseline participant characteristics

The baseline characteristics will be summarized according to the table below.

Table 8: Baseline characteristics of trial participants

	ITT population (n=)	
	Control (n=)	Intervention (n=)
Age, mean (SD)		
Number of days into pregnancy when recruited, mean (SD)		
Number of days until due date, mean (SD)		
Days since last puff, mean (SD)		
When did you quit smoking		
Before pregnancy, n(%)		
During pregnancy, n(%)		
Partner smoking status		
No partner, n(%)		
Smoker, n(%)		
Never smoker, n(%)		
Ex smoker, n(%)		
Highest qualification		
None, n(%)		
GCSE, n(%)		
A-level, n(%)		
Degree, n(%)		



Missing, n(%)		
Ethnicity		
White, n(%)		
Mixed, n(%)		
Asian / Asian British, n(%)		
Black/African/Caribbean/Black British, n(%)		
Arab, n(%)		
Any other ethnic group, n(%)		
Missing, n(%)		
Marital status		
Single, n(%)		
Co-habiting, n(%)		
Civil partnership, n(%)		
Married, n(%)		
Divorced, n(%)		
Widowed, n(%)		
Missing, n(%)		
Confidence not continue to smoke until baby's first birthday		
Not at all confident		
Slightly confident		
Moderately confident		
Very confident		
Extremely confident		
Use of Nicotine replacement therapy		
Have you used any Nicotine Replacement Therapy (NRT) in the last week?		
Did you use an e-cigarette to help you stop smoking?		
have you used an e-cigarette in the last week?		
Did you use a heat-not-burn product to help you stopsmoking?		
Have you used a heat-not burn product in the last week?		
Did you receive any professional help with stopping smoking?		
Do you still receive help from this organisation to stay smoke free?		
Are you currently using any apps which help with quittingsmoking or staying quit from smoking?		
Edinburgh post natal depression scale, mean (SD)		
PSS4 score		

6.0 Analysis



6.1 Outcome definitions

6.1.1 Primary Outcome

The primary effectiveness outcome is self-reported continuous postpartum smoking abstinence, biochemically validated by CO monitoring at 12 months postpartum, with cut off of less than 8ppm (i.e. a reading of 7ppm or less) for women who are not pregnant, or with a cut off of less than 4ppm if they are pregnant at this time point, according to the Russell standard (25,26). Adapting the Russell standard, we will grant a period of 'grace', allowing up to 5 smoking lapses between the birth of the baby and the 12 month follow-up, before the outcome is counted as relapse. Participants will provide CO readings electronically, using the iCO monitor (Bedfont) and study app (iCOBabyBreathe) provided at baseline. Participants will provide the REDCap database with two CO readings. Where CO readings take place in person as part of standard care, or research visits, these readings may be used.

This will be constructed from

- the question "Are you currently smoke free?" taking smoke free to be either
 - "Abstinent" with the answers "Yes I am smoke free - I have not smoked a cigarette in the last 12 months (not even a puff of a cigarette)" or "Yes I am smoke free currently but I have had between one and five lapses in the last 12 months (a cigarette, or puff of a cigarette)"; and
 - "relapse" to be either "Yes I am currently smoke free but I have had six or more lapses in the last 12 months (including relapse but quit again)" or "No, I am currently smoking tobacco"; and
- The CO readings will be classified as 'verified' if a reading of 7ppm or less; and 'not verified' if 8 or more. Missing values will be classified as 'not verified'

The primary outcome will be classified as "confirmed abstinent" if the participant's response is both "Abstinent" and "verified"; otherwise it will be classified "Not confirmed abstinent".

6.1.2 Secondary Outcomes

The secondary outcomes are measured at 6 and 12 months postpartum and are:

- Self-reported abstinence defined as reporting less than 5 lapses in the last 6 months at 6 months and at 12 months. [1 or 2 in fu6_smoking_status] [1 or 2 in fu12_smoking_status]
- Self-reported time to relapse defined as time from birth of child until individual self-reported date when started smoking again [fu_smoking_again_de] for individuals who report that they are currently smoking at either 6 or 12 months.
- Relapse predictors
 - Partner smoking status [fu_partner_smoke_yn]
 - Self-reported breast feeding at 6 and 12 months (yes/no)
 - Self-reported duration of breast feeding



- Self-efficacy to remain smoke free measured using the question ‘How confident are you that you will continue not to smoke at least until your baby’s first birthday?’ at 6 months and ‘How confident are you that you will continue not to smoke?’
- Postnatal depression measured the Edinburgh postnatal depression scale. This has 10 items and is scored using a scale ranging from 0 to 30 with high value indicating greater chance of depression. The scoring guide used will be
- Behavioral support use measured using the question ‘In the last 6 months have you received any professional help with stopping smoking, e.g. from NHS smokefree services?’ This will be analysed separately for
 - Smoking-free services
 - GP advice
 - Digital smokefree services
- Nicotine product use measure as use of Nicotine Replacement Therapy in the last 6 months.
- Nicotine product use measure as use of Nicotine Replacement Therapy in the last 7 days
- Perceived stress will be measured using Cohen PSS4 scale. This consists 4 items each scored 0-4, with the total score ranging from 0 to 16 with higher values indicates more stress.
- AUDIT-C this is a questionnaire based on 3 questions [alcohol_frequency_fu], [alcohol_units_fu] and [alcohol_6ormore_units] each scored 0-4 and the total is scored 0-12 with higher values indicating higher chance of possible dependence.
- EQ-5D-5L
- Infant health outcomes measured by
 - Number of hospital admissions
 - Number of GP visits
 - Length of stay when giving birth
 - Neonatal unit admission or not.
- E-cig use
 - In last 6 months
 - Frequency of use in last 6 months
 - In last 7 days

6.1.3 Tertiary outcomes

None.

6.2 Analysis Methods

6.2.1 Primary outcome

The primary outcome will be compared between treatment groups using a log-binomial regression adjusting for the stratification variables in a ‘minimally adjusted’ model; if adjustment for additional variables is recommended from the TSC prior to analysis this will be detailed in this document. This will allow the estimation of the relative risk of abstinence between the two treatment groups. The risk difference will be estimated from this model using the predicted risk, those factors in the model which are categorical will be set at the value with the largest number of participants and the continuous



factors will be set at the mean value. Any individual with missing data will be assumed to have relapsed, in the event of the abstinence not being able to be confirmed biochemically it will also be assumed to have been in relapse.

Table 6.2.1: Summary for primary outcome (will be reported for the ITT and ITT+ populations)

Outcome	ITT population		Minimally adjusted (only for stratification variables)			Fully adjusted		
	Control (n=)	Intervention (n=)	Relative risk (95% CI)	p-value	Difference in risk (95%CI)	Relative risk (95% CI)	p-value	Difference in risk (95%CI)
12 Month abstinence	n(%)	n(%)						

6.2.2 Secondary outcomes

The following tables give the analysis for each outcome listed in section 6.1.2

Outcome	Self-reported continuous postpartum smoking abstinence. CO verified
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	The effect size will also be estimated as the risk difference and 'number-needed-to-treat' using an unadjusted model. Biochemical validation of self-reported abstinence is the gold standard outcome assessment in smoking cessation/relapse prevention trials (27).

Outcome	6 month Self-reported continuous postpartum smoking abstinence
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.



Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	The effect size will also be estimated as the risk difference and 'number-need-to-treat' using an unadjusted model.

Outcome	Self-reported time-to-relapse, defined as the time from randomisation until the date first smoked
Effect size	Hazard ratio
Primary Analysis model	Cox regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Cox regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Individuals who drop-out will be assumed to have relapsed on the date of drop-out. Individuals who have not relapsed will be censored at the end of the study.
Other comments	Data will be presented graphically using a Kaplan-Meier Curve. Cox regression assumptions will be assessed visually using a plot of Schoenfeld residuals against follow-up time. If assumptions not met then other models adjustments to the model (treating variables as strata rather than covariates) will be attempted. If not possible then alternative modelling will be investigated.

Outcome	Participant reported partner smoking status at 6 and 12 months
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.



Other comments	Only to be analysed for individuals with a) the same partner status as at baseline; and b) the partner had quit by the date of randomisation
----------------	--

Outcome	Self-reported breastfeeding status
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Self-reported duration of breastfeeding (duration)
Effect size	Mean difference
Primary Analysis model	General linear model adjusting for factors stratified in the randomisation.
Sensitivity analysis	General linear model adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	

Outcome	Self-efficacy to remain smokefree
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Postpartum depression – Edinburgh postnatal depression questionnaire (39)
Effect size	Mean difference



Primary Analysis model	Linear regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Linear regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	Assumptions will be assessed via plots of residuals to check for normality. If not normally distributed a non-parametric bootstrap will be used or a Mann-Whitney test will be used.

Outcome	Access in-person smoke free services
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Access in-person GP advice for stop smoking
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Access digital smoke free services
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.



Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Nicotine product use in last 6 months
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Nicotine product use in last 7 days
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	Binary yes/no at 12 months

Outcome	Perceived Stress – Cohen perceived stress scale (41)
Effect size	Mean difference
Primary Analysis model	Linear regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Linear regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	Assumptions will be assessed via plots of residuals to check for normality. If not normally



	distributed a non-parametric bootstrap will be used or a Mann-Whitney test will be used.
--	--

Outcome	Alcohol Use (AUDIT-C) (40)
Effect size	None.
Primary Analysis model	Mann-Whitney test.
Sensitivity analysis	None.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	This outcome is unlikely to be normally distributed so a non-parametric approach will be used.

Outcome	Quality of life EQ-5D-5L
Effect size	Mean difference
Primary Analysis model	Linear regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Linear regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	Assumptions will be assess via plots of residuals to check for normality. If not normally distributed a non-parametric bootstrap will be used

Outcome	Number of hospital admission for child in follow-up period
Effect size	Incident rate ratio
Primary Analysis model	Poisson regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Poisson regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	Assumptions will be assessed and if a negative binomial model fits the data better then it will be used.



Outcome	Number of GP visits of child in follow-up period
Effect size	Incident rate ratio
Primary Analysis model	Poisson regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Poisson regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	Assumptions will be assessed and if a negative binomial model fits the data better then it will be used.

Outcome	Length of stay on birth
Effect size	Mean difference
Primary Analysis model	Linear regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Linear regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be assumed to have relapsed into smoking.
Other comments	Assumptions will be assessed via plots of residuals to check for normality. If not normally distributed a non-parametric bootstrap will be used

Outcome	Neonatal unit admission of child
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	

Outcome	E-cigarette use in 6 months
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.



Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	

Outcome	Frequency of using an 3-cigarette in past 6 months
Effect size	None.
Primary Analysis model	Mann-Whitney test.
Sensitivity analysis	None.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	This outcome is ordinally distributed so a non-parametric approach will be used.

Outcome	E-cigarette use in last week
Effect size	Relative risk
Primary Analysis model	Log-binomial regression adjusting for factors stratified in the randomisation.
Sensitivity analysis	Log-binomial regression adjusting for factors stratified in the randomisation and factors pre-specified by TMG before database lock.
Missing data	Missing data will be imputed in a sensitivity analysis.
Other comments	

Table 17: Secondary efficacy outcomes

Outcome	ITT population		Minimally adjusted		Fully adjusted	
	Control (n=)	Intervention (n=)	Effect size (95%CI)	p-value	Effect size (95%CI)	p-value



6.3 Missing Data

As mentioned in the above our primary analysis will replace missing abstinence values with relapse and the analysis of the other endpoints will be of available case. A sensitivity analysis will be conducted using multiple imputation assuming that the data are not missing at random. Alternative assumptions will be investigated but it will not be known which approaches/assumption are appropriate until we have more data about the missingness pattern. However, a reasonable NMAR choice would be to assume that those with missing data have worse outcome than those without missing data.

6.4 Additional analyses

6.5 Safety analyses

Only descriptive analysis of the SAE and SE will be reported. These will simply be listed as per the tables below.

Table 6.5.1: serious adverse events (incl. event description, duration, relationship to intervention)

Group	Date of onset	Description	Date of resolution	Related to trial treatment	Randomised group

Table 6.5.2: adverse events, by event, severity, or if appropriate, by relationship to intervention (including duration of treatment exposure), body compartment/system:

Group	Date of onset	Description	Date of resolution	Related to trial treatment	Randomised group

6.5 Software

Stata 17.1 or higher will be used for the majority of the analyses, however alternative software may be used if required.



7.0 References

Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. *Journal of Health and Social Behavior*, 24, 385-396.

Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. *British Journal of Psychiatry* 150:782-786.